Skip to content
DataLookout
Menu

LINKER-MM4NCT05828511

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 30 versions: 29 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 10 words
    • Enrollment closed, study ongoing
    • Enrollment target: estimated 149 to confirmed 148
    • Site details revised at 32 of 32 sites
  2. Minor Site details revised at 1 of 32 sitesv29
  3. Minor Study sites revised (32)v28
  4. Notable Eligibility criteria expanded, about 5 words
    • Enrollment target: 132 to 149
    • Secondary endpoints revised (28)
    • Primary endpoints revised (10)
    v27
  5. Minor Study sites: 30 to 32v26
Show 23 earlier versionsHide 23 earlier versions
  1. Minor Study sites revised (30)v25
  2. Minor Study sites revised (30)v23
  3. Minor Study sites: 29 to 30v22
  4. Minor Study sites: 28 to 29v21
  5. Minor Study sites revised (28)v20
  6. Minor Study sites: 27 to 28v19
  7. Minor Study sites: 26 to 27v18
  8. Minor Study sites: 22 to 26v17
  9. Minor Study sites: 19 to 22v16
  10. Minor Study sites: 18 to 19v15
  11. Minor Study sites: 15 to 18v14
  12. Minor Study sites: 11 to 15v13
  13. Minor Study sites: 10 to 11v12
  14. Minor Study sites: 9 to 10v11
  15. Minor Study sites: 8 to 9v10
  16. Minor Study sites: 5 to 8v9
  17. Notable Eligibility criteria expanded, about 7 wordsv8 Show 4 more changesShow less
    • Primary endpoints revised (10)
    • Study sites: 4 to 5
    • Secondary endpoints revised (28)
    • Study title expanded, about 1 word
  18. Minor Study sites: 2 to 4v7
  19. Minor Study sites: 1 to 2
    • Primary and study completion dates: Nov 30, 2035 to Nov 2, 2035
    • Start date changed from estimate of Jan 12, 2024 to Dec 19, 2023
    v6
  20. Notable Start date: Dec 8, 2023 to Jan 12, 2024
    • Primary and study completion dates: Oct 19, 2035 to Nov 30, 2035
    v5
  21. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: Nov 16, 2023 to Dec 8, 2023
    v4
  22. Minor Primary and study completion dates: Sep 30, 2035 to Oct 19, 2035
    • Start date: Oct 27, 2023 to Nov 16, 2023
    v3
  23. Notable Start date: Jul 31, 2023 to Oct 27, 2023
    • Primary and study completion dates: Jun 22, 2035 to Sep 30, 2035
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of Dose-Limiting Toxicities (DLTs)
Timeframe: End of the Observation period; up to day 28
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Timeframe: Post-Last Linvoseltamab Dose, up to 90 days
Severity of TEAEs
Timeframe: Post-Last Linvoseltamab Dose, up to 90 days
Incidence of Adverse Events of Special Interest (AESIs)
Timeframe: Post-Last Linvoseltamab Dose, up to 90 days
Severity of AESIs
Timeframe: Post-Last Linvoseltamab Dose, up to 90 days
Proportion of participants with a Very Good Partial Response (VGPR) or better using the International Myeloma Working Group (IMWG) response criteria
Timeframe: Up to 5 years
Proportion of participants achieving Minimal Residual Disease (MRD) negative status (at 10^-5) after induction with consolidation therapy
Timeframe: Up to 5 years
Proportion of participants achieving MRD-negative status (at 10^-5) after induction without consolidation therapy
Timeframe: Up to 5 years
Proportion of participants achieving MRD-negative status as their best response after treatment period I with continuing to treatment period II
Timeframe: Up to 5 years
Proportion of participants achieving MRD-negative status as their best response after treatment period I without continuing to treatment period II
Timeframe: Up to 5 years

Secondary (28)

Concentrations of Linvoseltamab in serum
Concentrations of total soluble B-Cell Maturation Antigen (BCMA)
Incidence of Anti-Drug Antibodies (ADAs) to Linvoseltamab
Magnitude of ADAs to Linvoseltamab
Objective Response Rate (ORR) measured using the IMWG criteria
Show 23 moreShow less
Duration Of Response (DOR) measured using the IMWG criteria
Progression-Free Survival (PFS) measured using the IMWG criteria
Proportion of participants achieving MRD-negative status (at 10^-5) in participants with NDMM measured using the IMWG criteria
Incidence of TEAEs
Severity of TEAEs
Incidence of AESIs
Severity of AESIs
ORR of participants deemed transplant-eligible and transplant-ineligible by the treating physician
MRD-negative status of participants deemed transplant-eligible and transplant-ineligible by the treating physician
DOR of participants deemed transplant-eligible and transplant-ineligible by the treating physician
PFS of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Overall Survival (OS) of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Time To Response (TTR) as measured using the IMWG criteria
ORR by risk levels
MRD-negative status by risk levels
DOR by risk levels
TTR by risk levels
PFS by risk levels
Incidence of MRD-negative status
Cluster of Differentiation 34+ (CD34+) stem cell yield
Time to neutrophil engraftment
Time to platelet engraftment
PFS after ASCT followed by 3 cycles of linvoseltamab

Arms and interventions

Phase 1 cohortsExperimental

Linvoseltamab dose escalation (part A), dose expansion (part B), and evaluation of alternative step-up regimen (part C) for participants with NDMM who are treatment-naïve.

Phase 2 - transplant ineligible cohortExperimental

Transplant-ineligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen until disease progression as per protocol.

Phase 2 - transplant eligible cohortExperimental

Transplant-eligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen for a fixed duration of treatment as per protocol

Drugs: Linvoseltamab

Sites

32 sites in 3 countries

United States 13, Spain 11, France 8